Macrocure Ltd Company Profile (NASDAQ:MCUR)

About Macrocure Ltd (MCUR)

Macrocure Ltd logoMacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MCUR
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $1.51
  • 50 Day Moving Average: $1.51
  • 200 Day Moving Average: $1.54
  • 52-Week Range: $0.75 - $3.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.72
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 0.62
Debt:
  • Current Ratio: 44.95%

Analyst Ratings

Consensus Ratings for Macrocure Ltd (NASDAQ:MCUR) (?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: $1.00 (33.77% downside)

Analysts' Ratings History for Macrocure Ltd (NASDAQ:MCUR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2016Credit Suisse Group AGDowngradeNeutral -> Underperform$1.00N/AView Rating Details
10/28/2015Jefferies Group LLCLower Price TargetHold$1.50N/AView Rating Details
8/20/2015Oppenheimer Holdings Inc.DowngradeOutperform -> Market Perform$20.00N/AView Rating Details
8/20/2015NomuraDowngradeBuy -> Neutral$20.00 -> $6.00N/AView Rating Details
(Data available from 3/25/2015 forward)

Earnings

Earnings History for Macrocure Ltd (NASDAQ:MCUR)
Earnings by Quarter for Macrocure Ltd (NASDAQ:MCUR)
Earnings History by Quarter for Macrocure Ltd (NASDAQ:MCUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2016        
11/17/2015Q3($0.36)($0.32)ViewN/AView Earnings Details
8/4/2015Q215($0.37)($0.37)ViewListenView Earnings Details
5/11/2015Q115($0.38)($0.38)$0.01 millionViewN/AView Earnings Details
3/17/2015Q414($0.32)($0.42)ViewN/AView Earnings Details
11/3/2014Q314($0.31)($0.70)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Macrocure Ltd (NASDAQ:MCUR)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS

Dividends

Dividend History for Macrocure Ltd (NASDAQ:MCUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Macrocure Ltd (NASDAQ:MCUR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Macrocure Ltd (NASDAQ:MCUR)
Latest Headlines for Macrocure Ltd (NASDAQ:MCUR)
Source:
DateHeadline
streetinsider.com logoMacrocure (MCUR) Completes Merger with Leap Therapeutics
www.streetinsider.com - January 23 at 11:46 PM
streetinsider.com logoMacrocure (MCUR) Completes Merger with Leap Therapeutics - StreetInsider.com
www.streetinsider.com - January 23 at 6:44 PM
us.rd.yahoo.com logoMacrocure and Leap Therapeutics Complete Merger
us.rd.yahoo.com - January 23 at 10:15 AM
finance.yahoo.com logoLeap Therapeutics and Macrocure Complete Merger Transaction
finance.yahoo.com - January 23 at 10:15 AM
streetinsider.com logoLeap Presents Biomarker Data from Study of DKN-01 Combo with Paclitaxel in Esophageal Cancer (MCUR) - StreetInsider.com
www.streetinsider.com - January 20 at 1:28 AM
us.rd.yahoo.com logoLeap Therapeutics Presents Biomarker Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer
us.rd.yahoo.com - January 19 at 8:28 PM
us.rd.yahoo.com logo3:33 pm Macrocure: Leap Therapeutics reported updated clinical and biomarker data from an ongoing study of DKN-01 in patients with cancer of the esophagus and gastroesophageal junction
us.rd.yahoo.com - January 19 at 8:28 PM
prnewswire.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of The Board of Directors of ... - PR Newswire (press release)
www.prnewswire.com - December 1 at 6:26 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of The Board of Directors of Macrocure Ltd.- MCUR
finance.yahoo.com - November 29 at 2:57 PM
finance.yahoo.com logoMacrocure Announces New Date for Special General Meeting of Shareholders to Approve Merger With Leap Therapeutics
finance.yahoo.com - November 25 at 11:19 AM
finance.yahoo.com logo8:10 am Macrocure delayed the scheduled date for its previously-announced special general meeting of shareholders regarding Leap Therapeutics merger approval by one week
finance.yahoo.com - November 25 at 11:19 AM
businesswire.com logoLeap Therapeutics Presents Data from Phase 1 Study of GITR Agonist
www.businesswire.com - November 12 at 6:12 PM

Social

Frequently Asked Questions for Macrocure Ltd (NASDAQ:MCUR)

What is Macrocure Ltd's stock symbol?

Macrocure Ltd trades on the NASDAQ under the ticker symbol "MCUR."

How were Macrocure Ltd's earnings last quarter?

Macrocure Ltd (NASDAQ:MCUR) released its quarterly earnings data on Tuesday, November, 17th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04.

When will Macrocure Ltd make its next earnings announcement?

Macrocure Ltd is scheduled to release their next quarterly earnings announcement on Wednesday, March, 16th 2016.

Where is Macrocure Ltd's stock going? Where will Macrocure Ltd's stock price be in 2017?

1 analysts have issued 12-month target prices for Macrocure Ltd's shares. Their predictions range from $1.00 to $1.00. On average, they anticipate Macrocure Ltd's stock price to reach $1.00 in the next twelve months.

Who owns Macrocure Ltd stock?

Macrocure Ltd's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.00%).

Who bought Macrocure Ltd stock? Who is buying Macrocure Ltd stock?

Macrocure Ltd's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy Macrocure Ltd stock?

Shares of Macrocure Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Macrocure Ltd stock cost?

One share of Macrocure Ltd stock can currently be purchased for approximately $1.51.

Macrocure Ltd (MCUR) Chart for Saturday, March, 25, 2017

This page was last updated on 3/25/2017 by MarketBeat.com Staff